These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis. Krüüner A; Pehme L; Ghebremichael S; Koivula T; Hoffner SE; Mikelsaar M Clin Infect Dis; 2002 Jul; 35(2):146-55. PubMed ID: 12087520 [TBL] [Abstract][Full Text] [Related]
63. [Studies on short-course chemotherapy of tuberculosis. II. Liver function during 6-month chemotherapy of tuberculosis with hydrazide, rifampicin and pyrazinamide]. Nikodemowicz E; Kamińska M; Caban M; Struzik T Pneumonol Pol; 1984 Oct; 52(10):503-12. PubMed ID: 6533580 [No Abstract] [Full Text] [Related]
64. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? Wilkinson D; Bechan S; Connolly C; Standing E; Short GM Int J Tuberc Lung Dis; 1998 Jan; 2(1):52-5. PubMed ID: 9562111 [TBL] [Abstract][Full Text] [Related]
66. [Chemotherapeutic treatment of pulmonary tuberculosis]. Blanco Quirós A An Esp Pediatr; 1985 Jun; 22(8):547-50. PubMed ID: 3931527 [No Abstract] [Full Text] [Related]
67. [Current status of the antitubercular chemotherapy]. Radenbach KL Internist (Berl); 1973 Mar; 14(3):100-10. PubMed ID: 4573242 [No Abstract] [Full Text] [Related]
68. Rifampin: clinical experience with a new anti-tuberculosis drug. Raleigh JW Trans Am Clin Climatol Assoc; 1972; 83():104-12. PubMed ID: 5040107 [No Abstract] [Full Text] [Related]
69. Short-course treatment in pulmonary tuberculosis. East Afr Med J; 1977 Feb; 54(2):53-60. PubMed ID: 69524 [No Abstract] [Full Text] [Related]
70. [Ambulatory chemotherapy of tuberculosis]. Sighart H Wien Med Wochenschr; 1972 Dec; 122(51):781-3. PubMed ID: 4650077 [No Abstract] [Full Text] [Related]
71. [Effects of intermittent short-course chemotherapy under full-course supervision on the treatment of smear positive pulmonary tuberculosis]. Yan S; Ye H; Lin S Zhonghua Jie He He Hu Xi Za Zhi; 1996 Apr; 19(2):104-6. PubMed ID: 9388851 [TBL] [Abstract][Full Text] [Related]
72. Response to short-course chemotherapy of patients with initial resistance to antituberculosis drugs. Valenzuela P; Valenzuela MT; Ponce J Bull Pan Am Health Organ; 1988; 22(2):175-83. PubMed ID: 3048504 [No Abstract] [Full Text] [Related]
73. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398 [TBL] [Abstract][Full Text] [Related]
74. Multiple small bowel perforations in a patient on treatment of tuberculosis. Scriven JM; Berry D J R Coll Surg Edinb; 1996 Oct; 41(5):353. PubMed ID: 8908966 [TBL] [Abstract][Full Text] [Related]
75. [Acute respiratory distress syndrome: a manifestation of immune reconstitution in an HIV-negative patient with tuberculosis]. Wikman PE; Jover F; Peris J; Cuadrado JM Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):132-3. PubMed ID: 19254644 [No Abstract] [Full Text] [Related]
76. Pyrazinamide serum levels in childhood tuberculosis. Thee S; Detjen A; Wahn U; Magdorf K Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511 [TBL] [Abstract][Full Text] [Related]
77. [Operational aspects in the implementation of short-term antituberculous treatment]. Pacheco CR Salud Publica Mex; 1985; 27(1):31-9. PubMed ID: 3992356 [No Abstract] [Full Text] [Related]